Drug efflux transporters in the CNS

Advanced Drug Delivery Reviews

Volumn 55, Issue 1, 2003, Pages 83-105

  Sun, Haiying ^a   Dai, Haiqing ^a   Shaik, Naveed ^a   Elmquist, William F ^a  

^a UNIVERSITY OF NEBRASKA MEDICAL CENTER   (United States)

Author keywords

Blood brain barrier; Blood CSF barrier; Central nervous system; Efflux transport proteins; Organic anion transporters; p Glycoprotein

Indexed keywords

BRAIN; CELLS; DISEASES; DRUG INTERACTIONS; TOXIC MATERIALS; TRANSPORT PROPERTIES;

DRUG DISTRIBUTION;

NEUROLOGY;

ABC TRANSPORTER; ANTICONVULSIVE AGENT; ANTIDIARRHEAL AGENT; ANTIGOUT AGENT; ANTILIPEMIC AGENT; ANTINEOPLASTIC AGENT; CARDIAC AGENT; CYCLOPROPYLIBENZOSUBERANE; CYCLOSPORIN A; ELACRIDAR; FLUORESCENT DYE; GLYCOPROTEIN P; IMMUNOSUPPRESSIVE AGENT; KETOCONAZOLE; MIFEPRISTONE; MULTIDRUG RESISTANCE PROTEIN; NEUROTOXIN; POLYPEPTIDE; PROTEIN INHIBITOR; PROTEINASE INHIBITOR; QUINIDINE; REVERSIN 121; REVERSIN 125; STEROID; TUBERCULOSTATIC AGENT; UNCLASSIFIED DRUG; UNINDEXED DRUG; VALSPODAR; XENOBIOTIC AGENT; XR 5944; XR 9544; ZOSUQUIDAR;

ANION TRANSPORT; BLOOD BRAIN BARRIER; BLOOD CEREBROSPINAL FLUID BARRIER; BRAIN PROTECTION; CAPILLARY ENDOTHELIUM; CENTRAL NERVOUS SYSTEM; DRUG DELIVERY SYSTEM; DRUG DISTRIBUTION; DRUG ELIMINATION; DRUG PENETRATION; DRUG TRANSPORT; DRUG UPTAKE; ENDOTHELIUM CELL; HOMEOSTASIS; HUMAN; IN VITRO STUDY; IN VIVO STUDY; LIPOPHILICITY; NONHUMAN; PRIORITY JOURNAL; REVIEW; TRANSPORT KINETICS;

ANIMALS; BIOLOGICAL TRANSPORT, ACTIVE; BLOOD-BRAIN BARRIER; CENTRAL NERVOUS SYSTEM; CLINICAL TRIALS; DRUG RESISTANCE, MULTIPLE; HUMANS; ORGANIC ANION TRANSPORTERS; P-GLYCOPROTEIN; SUBSTRATE SPECIFICITY;

EID: 0037457803     PISSN: 0169409X     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0169-409X(02)00172-2     Document Type: Article

References (233)

1. Levin V.A. Relationship of octanol/water partition coefficient and molecular weight to rat brain capillary permeability. J. Med. Chem. 23:(6):1980;682-684.
2. Pardridge W.M. CNS drug design based on principles of blood-brain barrier transport. J. Neurochem. 70:1998;1781-1792.
3. Lee G., Dallas S., Hong M., Bendayan R. Drug transporters in the central nervous system: Brain barriers and brain parenchyma considerations. Pharmacol. Rev. 53:(4):2001;569-596.
4. Kusuhara H., Sugiyama Y. Efflux transport systems for drugs at the blood-brain barrier and blood-cerebrospinal fluid barrier (Part 1). Drug. Discov. Today. 6:(3):2001;150-156.
5. Kusuhara H., Sugiyam Y. Efflux transport systems for drugs at the blood-brain barrier and blood-cerebrospinal fluid barrier (Part 2). Drug. Discov. Today. 6:(4):2001;206-212.
6. Tanigawara Y. Role of P-glycoprotein in drug disposition. Ther. Drug Monit. 22:(1):2000;137-140.
7. Kusuhara H., Sugiyama Y. Role of transporters in the tissue-selective distribution and elimination of drugs: Transporters in the liver, small intestine, brain and kidney. J. Controlled Release. 78:(1-3):2002;43-54.
8. Schinkel A.H. The physiological function of drug transporting P-glycoproteins. Semin. Cancer Biol. 8:(3):1997;161-170.
9. Ayrton A., Morgan P. Role of transport proteins in drug absorption, distribution and excretion. Xenobiotica. 319:(8-9):2001;469-497.
10. Tamai I., Tsuji A. Transporter-mediated permeation of drugs across the blood-brain barrier. J. Pharm. Sci. 89:(11):2000;1371-1388.
11. Tsuji A., Tamai I. Carrier-mediated or specialized transport of drugs across the blood-brain barrier. Adv. Drug Deliv. Rev. 36:(2-3):1999;277-290.
12. Sugiyama Y., Kusuhara H., Suzuki H. Kinetic and biochemical analysis of carrier-mediated efflux of drugs through the blood-brain and blood-cerebrospinal fluid barriers: Importance in the drug delivery to the brain. J. Controlled Release. 62:(1-2):1999;179-186.
13. Taylor E.M. The impact of efflux transporters in the brain on the development of drugs for CNS disorders. Clin. Pharmacokinet. 41:(2):2002;81-92.
14. van Asperen J., Mayer U., van Tellingen O., Beijnen J.H. The functional role of P-glycoprotein in the blood-brain barrier. J. Pharm. Sci. 86:(8):1997;881-884.
15. Terasaki T., Hosoya K. The blood-brain barrier efflux transporters as a detoxifying system for the brain. Adv. Drug Deliv. Rev. 5:(36):1999;195-209.
16. Gao B., Meier P.J. Organic anion transport across the choroids plexus. Microsc. Res. Tech. 52:(1):2001;60-64.
17. Juliano R.L., Ling V. A surface glycoprotein modulating drug permeability in Chinese hamster ovary cell mutants. Biochim. Biophys. Acta. 455:(1):1976;152-162.
18. Kartner N., Shales M., Riordan J.R., Ling V. Daunorubicin-resistant Chinese hamster ovary cells expressing multidrug resistance and a cell-surface P-glycoprotein. Cancer Res. 43:(9):1983;4413-4419.
19. Fromm M.F. P-glycoprotein: A defense mechanism limiting oral bioavailability and CNS accumulation of drugs. Int. J. Clin. Pharmacol. Ther. 38:(2):2000;69-74.
20. Seelig A. A general pattern for substrate recognition by P-glycoprotein. Eur J. Biochem. 251:(1-2):1998;252-261.
21. Ambudkar S.V., Dey S., Hrycyna C.A., Ramachandra M., Pastan I., Gottesman M.M. Biochemical, cellular, and pharmacological aspects of the multidrug transporter. Annu. Rev. Pharmacol. Toxicol. 39:1999;361-398.
22. Ekins S., Kim R.B., Leake B.F., Dantzig A.H., Schuetz E.G., Lan L.B., Yasuda K., Shepard R.L., Winter M.A., Schuetz J.D., Wikel J.H., Wrighton S.A. Three-dimensional quantitative structure-activity relationships of inhibitors of P-gp. Mol. Pharmacol. 61:(5):2002;964-973.
23. Ekins S., Kim R.B., Leake B.F., Dantzig A.H., Schuetz E.G., Lan L.B., Yasuda K., Shepard R.L., Winter M.A., Schuetz J.D., Wikel J.H., Wrighton S.A. Application of three-dimensional quantitative structure-activity relationships of p-glycoprotein inhibitors and substrates. Mol. Pharmacol. 61:(5):2002;974-981.
24. Cordon-Cardo C., O'Brien J.P., Casals D., Rittman-Grauer L., Biedler J.L., Melamed M.R., Bertino J.R. Multidrug-resistance gene (P-glycoprotein) is expressed by endothelial cells at blood-brain barrier sites. Proc. Natl. Acad. Sci. USA. 86:(2):1989;695-698.
25. Thiebaut F., Tsuruo T., Hamada H., Gottesman M.M., Pastan I., Willingham M.C. Immunohistochemical localization in normal tissues of different epitopes in the multidrug transport protein P170: Evidence for localization in brain capillaries and crossreactivity of one antibody with a muscle protein. J. Histochem. Cytochem. 37:(2):1989;159-164.
26. Sugawara I. Expression and functions of P-glycoprotein (mdr1 gene product) in normal and malignant tissues. Acta. Pathol. Jpn. 40:(8):1990;545-553.
27. van der Valk P., van Kalken C.K., Ketelaars H., Broxterman H.J., Scheffer G., Kuiper C.M., Tsuruo T., Lankelma J., Meijer C.J., Pinedo H.M., et al. Distribution of multidrug resistance-associated P-glycoprotein in normal and neoplastic human tissues. Analysis with 3 monoclonal antibodies recognizing different epitopes of the P-glycoprotein molecule. Ann. Oncol. 1:(1):1990;56-64.
28. Becker I., Becker K.F., Meyermann R., Hollt V. The multidrug-resistance gene MDR1 is expressed in human glial tumors. Acta Neuropathol. (Berl). 82:(6):1991;516-519.
29. Nabors M.W., Griffin C.A., Zehnbauer B.A., Hruban R.H., Phillips P.C., Grossman S.A., Brem H., Colvin O.M. Multidrug resistance gene (MDR1) expression in human brain tumors. J. Neurosurg. 75:(6):1991;941-946.
30. Tanaka Y., Abe Y., Tsugu A., Takamiya Y., Akatsuka A., Tsuruo T., Yamazaki H., Ueyama Y., Sato O., Tamaoki N., et al. Ultrastructural localization of P-glycoprotein on the capillary endothelial cells in human gliomas. Virchows Arch. 425:(2):1994;133-138.
31. Toth K., Vaughan M.M., Peress N.S., Slocum H.K., Rustum Y.M. MDR1 P-glycoprotein is expressed by endothelial cells of newly formed capillaries in human gliomas but is not expressed in the neovasculature of other primary tumors. Am. J. Pathol. 149:(3):1996;853-858.
32. Biegel D., Spencer D.D., Pachter J.S. Isolation and culture of human brain microvessel endothelial cells for the study of blood-brain barrier properties in vitro. Brain Res. 692:(1-2):1995;183-189.
33. Barrand M.A., Robertson K.J., von Weikersthal S.F. Comparisons of P-glycoprotein expression in isolated rat brain microvessels and in primary cultures of endothelial cells derived from microvasculature of rat brain, epididymal fat pad and from aorta. FEBS Lett. 374:(2):1995;179-183.
34. Jette L., Murphy G.F., Leclerc J.M., Beliveau R. Interaction of drugs with P-glycoprotein in brain capillaries. Biochem. Pharmacol. 50:(10):1995;1701-1709.
35. Hegmann E.J., Bauer H.C., Kerbel R.S. Expression and functional activity of P-glycoprotein in cultured cerebral capillary endothelial cells. Cancer Res. 52:(24):1992;6969-6975.
36. Shirai A., Naito M., Tatsuta T., Dong J., Hanaoka K., Mikami K., Oh-hara T., Tsuruo T. Transport of cyclosporin A across the brain capillary endothelial cell monolayer by P-glycoprotein. Biochim. Biophys. Acta. 1222:(3):1994;400-404.
37. Tsuji A., Terasaki T., Takabatake Y., Tenda Y., Tamai I., Yamashima T., Moritani S., Tsuruo T., Yamashita J. P-glycoprotein as the drug efflux pump in primary cultured bovine brain capillary endothelial cells. Life Sci. 51:(18):1992;1427-1437.
38. Tsuji A., Tamai I., Sakata A., Tenda Y., Terasaki T. Restricted transport of cyclosporin A across the blood-brain barrier by a multidrug transporter, P-glycoprotein. Biochem. Pharmacol. 46:(6):1993;1096-1099.
39. Jette L., Tetu B., Beliveau R. High levels of P-glycoprotein detected in isolated brain capillaries. Biochim. Biophys. Acta. 1150:(2):1993;147-154.
40. Beaulieu E., Demeule M., Ghitescu L., Beliveau R. P-glycoprotein is strongly expressed in the luminal membranes of the endothelium of blood vessels in the brain. Biochem. J. 326:(Pt 2):1997;539-544.
41. Pardridge W.M., Golden P.L., Kang Y.S., Bickel U. Brain microvascular and astrocyte localization of P-glycoprotein. J. Neurochem. 68:(3):1997;1278-1285.
42. Golden P.L., Pardridge W.M. P-Glycoprotein on astrocyte foot processes of unfixed isolated human brain capillaries. Brain Res. 819:(1-2):1999;143-146.
43. Golden P.L., Pardridge W.M. Brain microvascular P-glycoprotein and a revised model of multidrug resistance in brain. Cell Mol. Neurobiol. 20:(2):2000;165-181.
44. Lee G., Schlichter L., Bendayan M., Bendayan R. Functional expression of P-glycoprotein in rat brain microglia. J. Pharmacol. Exp. Ther. 299:(1):2001;204-212.
45. Murata M., Tamai I., Kato H., Nagata O., Tsuji A. Efflux transport of a new quinolone antibacterial agent, HSR-903, across the blood-brain barrier. J. Pharmacol. Exp. Ther. 290:(1):1999;51-57.
46. Cox D.S., Scott K.R., Gao H., Raje S., Eddington N.D. Influence of multidrug resistance (MDR) proteins at the blood-brain barrier on the transport and brain distribution of enaminone anticonvulsants. J. Pharm. Sci. 90:(10):2001;540-552.
47. Miller D.S., Graeff C., Droulle L., Fricker S., Fricker G. Xenobiotic efflux pumps in isolated fish brain capillaries. Am. J. Physiol. Regul. Integr. Comp. Physiol. 282:(1):2002;R191-198.
48. Chishty M., Reichel A., Siva J., Abbott N.J., Begley D.J. Affinity for the P-glycoprotein efflux pump at the blood-brain barrier may explain the lack of CNS side-effects of modern antihistamines. J. Drug Target. 9:(3):2001;223-228.
49. Hosoya K.I., Takashima T., Tetsuka K., Nagura T., Ohtsuki S., Takanaga H., Ueda M., Yanai N., Obinata M., Terasaki T. mRNA expression and transport characterization of conditionally immortalized rat brain capillary endothelial cell lines; a new in vitro BBB model for drug targeting. J. Drug Target. 8:(6):2000;357-370.
50. Fontaine M., Elmquist W.F., Miller D.W. Use of rhodamine 123 to examine the functional activity of P-glycoprotein in primary cultured brain microvessel endothelial cell monolayers. Life Sci. 59:(18):1996;521-531.
51. Batrakova E.V., Li S., Vinogradov S.V., Alakhov V.Y., Miller D.W., Kabanov A.V. Mechanism of pluronic effect on P-glycoprotein efflux system in blood-brain barrier: Contributions of energy depletion and membrane fluidization. J. Pharmacol. Exp. Ther. 299:(2):2001;483-493.
52. Fenart L., Buee-Scherrer V., Descamps L., Duhem C., Poullain M.G., Cecchelli R., Dehouck M.P. Inhibition of P-glycoprotein: Rapid assessment of its implication in blood-brain barrier integrity and drug transport to the brain by an in vitro model of the blood-brain barrier. Pharm. Res. 15:(7):1998;993-1000.
53. Gaillard P.J., van der Sandt I.C., Voorwinden L.H., Vu D., Nielsen J.L., de Boer A.G., Breimer D.D. Astrocytes increase the functional expression of P-glycoprotein in an in vitro model of the blood-brain barrier. Pharm. Res. 17:(10):2000;1198-1205.
54. Megard I., Garrigues A., Orlowski S., Jorajuria S., Clayette P., Ezan E., Mabondzo A. A co-culture-based model of human blood-brain barrier: Application to active transport of indinavir and in vivo-in vitro correlation. Brain Res. 927:(2):2002;153-167.
55. Tatsuta T., Naito M., Oh-hara T., Sugawara I., Tsuruo T. Functional involvement of P- glycoprotein in blood-brain barrier. J. Biol. Chem. 267:(28):1992;20383-20391.
56. Decleves X., Regina A., Laplanche J.L., Roux F., Boval B., Launay J.M., Scherrmann J.M. Functional expression of P-glycoprotein and multidrug resistance-associated protein (Mrp1) in primary cultures of rat astrocytes. J. Neurosci. Res. 60:2000;594-601.
57. Demeule M., Labelle M., Regina A., Berthelet F., Beliveau R. Isolation of endothelial cells from brain, lung, and kidney: Expression of the multidrug resistance P-glycoprotein isoforms. Biochem. Biophys. Res. Commun. 281:(3):2001;827-834.
58. El Hafny B., Chappey O., Piciotti M., Debray M., Boval B., Roux F. Modulation of P-glycoprotein activity by glial factors and retinoic acid in an immortalized rat brain microvessel endothelial cell line. Neurosci. Lett. 236:(2):1997;107-111.
59. Yang J., Mutkus L.A., Sumner D., Stevens J.T., Eldridge J.C., Strandhoy J.W., Aschner M. Transendothelial permeability of chlorpyrifos in RBE4 monolayers is modulated by astrocyte-conditioned medium. Brain Res. Mol. Brain. Res. 97:(1):2001;43-50.
60. Sobue K., Yamamoto N., Yoneda K., Hodgson M.E., Yamashiro K., Tsuruoka N., Tsuda T., Katsuya H., Miura Y., Asai K., Kato T. Induction of blood-brain barrier properties in immortalized bovine brain endothelial cells by astrocytic factors. Neurosci. Res. 35:(2):1999;155-164.
61. Gaillard P.J., Voorwinden L.H., Nielsen J.L., Ivanov A., Atsumi R., Engman H., Ringbom C., de Boer A.G., Breimer D.D. Establishment and functional characterization of an in vitro model of the blood-brain barrier, comprising a co-culture of brain capillary endothelial cells and astrocytes. Eur. J. Pharm. Sci. 12:(3):2001;215-222.
62. Hayashi Y., Nomura M., Yamagishi S., Harada S., Yamashita J., Yamamoto H. Induction of various blood-brain barrier properties in non-neural endothelial cells by close apposition to co-cultured astrocytes. Glia. 19:(1):1997;13-26.
63. Rao V.V., Dahlheimer J.L., Bardgett M.E., Snyder A.Z., Finch R.A., Sartorelli A.C., Piwnica-Worms D. Choroid plexus epithelial expression of MDR1 P glycoprotein and multidrug resistance-associated protein contribute to the blood-cerebrospinal-fluid drug-permeability barrier. Proc. Natl. Acad. Sci. USA. 96:(7):1999;3900-3905.
64. Warren K.E., Patel M.C., McCully C.M., Montuenga L.M., Balis F.M. Effect of P-glycoprotein modulation with cyclosporin A on cerebrospinal fluid penetration of doxorubicin in nonhuman primates. Cancer Chemother. Pharmacol. 45:(3):2000;207-212.
65. Gumbleton M., Audus K.L. Progress and limitations in the use of in vitro cell cultures to serve as permeability screen for the blood-brain barrier. J. Pharm. Sci. 90:(11):2001;1681-1698.
66. Audus K.L., Borchardt R.T. Bovine brain microvessel endothelial cell monolayers as a model system for the blood-brain barrier. Ann. NY Acad. Sci. 507:1987;9-18.
67. Johnson M.D., Anderson B.D. In vitro models of the blood-brain barrier to polar permeants: Comparison of transmonolayer flux measurements and cell uptake kinetics using cultured cerebral capillary endothelial cells. J. Pharm. Sci. 88:(6):1999;620-625.
68. Miller D.W., Audus K.L., Borchardt R.T. Application of cultured endothelial cells of the brain microvasculature in the study of the blood-brain barrier. J. Tiss. Cult. Meth. 14:1992;217-224.
69. Ichikawa N., Naora K., Hirano H., Hashimoto M., Masumara S., Iwamoto K. Isolation and primary culture of rat cerebral microvascular endothelial cells for studying drug transport in vitro. J. Pharmacol. Toxicol. Methods. 36:(1):1996;45-52.
70. Galla F.H., Beuckmann C.T. Primary cultures of brain microvessel endothelial cells: A valid and flexible model to study drug transport through the blood-brain barrier in vitro. Brain Res. Prot. 5:(3):2000;248-256.
71. Ghazanfari F.A., Stewart R.R. Characteristics of endothelial cells derived from the blood-brain barrier and of astrocytes in culture. Brain Res. 890:2001;49-65.
72. Begley D.J., Lechardeur D., Chen Z.D., Rollinson C., Bardoul M., Roux F., Scherman D., Abbott N.J. Functional expression of P-glycoprotein in an immortalised cell line of rat brain endothelial cells, RBE4. J. Neurochem. 67:(3):1996;988-995.
73. Regina A., Romero I.A., Greenwood J., Adamson P., Bourre J.M., Couraud P.O., Roux F. Dexamethasone regulation of P-glycoprotein activity in an immortalized rat brain endothelial cell line, GPNT. J. Neurochem. 73:(5):1999;1954-1963.
74. Terasaki T., Hosoya K. Conditionally immortalized cell lines as a new in vitro model for the study of barrier functions. Biol. Pharm. Bull. 24:(2):2001;111-118.
75. Pardridge W.M., Triguero D., Yang J., Cancilla P.A. Comparison of in vitro and in vivo models of drug transcytosis through the blood-brain barrier. J. Pharmacol. Exp. Ther. 253:(2):1990;884-891.
76. Hansen D.K., Scott D.O., Otis K.W., Lunte S.M. Comparison of in vitro BBMEC permeability and in vivo CNS uptake by microdialysis sampling. J. Pharm. Biomed. Anal. 27:(6):2002;945-958.
77. Glynn S.L., Yazdanian M. In vitro blood-brain barrier permaeability of nevirapine compared to other HIV antiretroviral agents. J. Pharm. Sci. 87:(3):1998;306-310.
78. van der Sandt I.C., Vos C.M., Nabulsi L., Blom-Roosemalen M.C., Voorwinden H.H., de Boer A.G., Breimer D.D. Assessment of active transport of HIV protease inhibitors in various cell lines and the in vitro blood-brain barrier. AIDS. 15:(4):2001;483-491.
79. Elmquist W.F., Miller D.W. The use of transgenic animals for pharmacokinetics and pharmacodynamics studies. J. Pharm. Sci. 90:2001;422-435.
80. Schinkel A.H., Smit J.J., van Tellingen O., Beijnen J.H., Wagenaar E., van Deemter L., Mol C.A., van der Valk M.A., Robanus-Maandag E.C., te Riele H.P., et al. Disruption of the mouse mdr1a P-glycoprotein gene leads to a deficiency in the blood-brain barrier and to increased sensitivity to drugs. Cell. 77:(4):1994;491-502.
81. Schinkel A.H., Wagenaar E., van Deemter L., Mol C.A., Borst P. Absence of the mdr1a P-glycoprotein in mice affects tissue distribution and pharmacokinetics of dexamethasone, digoxin, and cyclosporin A. J. Clin. Invest. 96:(4):1995;1698-1705.
82. Schinkel A.H., Wagenaar E., Mol C.A., van Deemter L. P-glycoproetin in the blood-brain barrier of mice influences the brain penetration and pharmacological activity of many drugs. J. Clin. Invest. 97:(11):1996;2517-2524.
83. van Asperen J., Schinkel A.H., Beijnen J.H., Nooijen W.J., Borst P., van Tellingen O. Altered pharmacokinetics of vinblastine in Mdr1a-P-glycoprotein-deficient Mice. J. Nat. Cancer Inst. 88:(14):1996;994-999.
84. van Asperen J., van Tellingen O., Schinkel A.H., Beijnen J.H. Comparative pharmacokinetics of vinblastine after a 96-h continuous infusion in wild-type mice and mice lacking mdr1a P-glycoprotein. J. Pharmacol. Exp. Ther. 289:(1):1999;329-333.
85. Schinkel A.H., Mayer U., Wagenaar E., Mol C.A., van Deemter L., Smit J.J., van der Valk M.A., Voordouw A.C., Spits H., van Tellingen O., Zijlmans J.M., Fibbe W.E., Borst P. Normal viability and altered pharmacokinetics in mice lacking mdr1-type (drug-transporting) P-glycoproteins. Proc. Natl. Acad. Sci. 94:(8):1997;4028-4033.
86. Kawahara M., Sakata A., Miyashita T., Tamai I., Tsuji A. Physiologically based pharmacokinetics of digoxin in mdr1a knockout mice. J. Pharm. Sci. 88:(12):1999;1281-1287.
87. Kim R.B., Fromm M.F., Wandel C., Leake B., Wood A.J., Roden D.M., Wilkinson G.R. The drug transporter P-glycoprotein limits oral absorption and brain entry of HIV-1 protease inhibitors. J. Clin. Invest. 101:(2):1998;289-294.
88. Polli J.W., Jarrett J.L., Studenberg S.D., Humphreys J.E., Dennis S.W., Brouwer K.R., Woolley J.L. Role of P-glycoprotein on the CNS disposition of amprenavir (141W94), an HIV protease inhibitor. Pharm. Res. 16:(8):1999;1206-1212.
89. Huisman M.T., Smit J.W., Wiltshire H.R., Hoetelmans R.M., Beijnen J.H., Schinkel A.H. P-glycoprotein limits oral availability, brain and fetal penetration of saquinavir even with high doses of ritonavir. Mol. Pharmacol. 59:(4):2001;806-813.
90. Jonkers J.W., Wagenaar E., van Deemter L., Gottschlich R., Bender H.M., Dasenbrock J., Schinkel A.H. Role of blood-brain barrier P-glycoprotein in limiting brain accumulation and sedative side-effects of asimadoline, a peripherally acting analgaesic drug. Br. J. Pharmacol. 127:(1):1999;43-50.
91. Yokogawa K., Takahashi M., Tamai I., Konishi H., Nomura M., Moritani S., Miyamoto K. P-glycoprotein-dependent disposition kinetics of tacrolimus: Studies in mdr1a knockout mice. Pharm. Res. 16:(8):1999;1213-1218.
92. Xie R., Hammarlund-Udenaes M., de Boer A.G., de Lange E.C. The role of P-glycoprotein in blood-brain barrier transport of morphine: Transcortical microdialysis studies in mdr1a (-/-) and mdr1a (+/+) mice. Br. J. Pharmacol. 128:(3):1999;563-568.
93. Dagenais C., Zong J., Ducharme J., Pollack G.M. Effect of mdr1a P-glycoprotein gene disruption, gender, and substrate concentration on brain uptake of selected compounds. Pharm. Res. 18:(7):2001;957-963.
94. Cisternino S., Rousselle C., Dagenais C., Scherrmann J.M. Screening of multidrug-resistance sensitive drugs by in situ brain perfusion in P-glycoprotein-deficient mice. Pharm. Res. 18:(2):2001;183-190.
95. Uhr M., Steckler T., Yassouridis A., Holsboer F. Penetration of amitriptyline, but not of fluoxetine, into brain is enhanced in mice with blood-brain barrier deficiency due to mdr1a P-glycoprotein gene disruption. Neuropsychopharmacology. 22:(4):2000;380-387.
96. de Lange E.C., Marchand S., van den Berg D., van der Sandt I.C., de Boer A.G., Delon A., Bouquet S., Couet W. In vitro and in vivo investigations on fluoroquinolones; effects of the P-glycoprotein efflux transporter on brain distribution of sparfloxacin. Eur. J. Pharm. Sci. 12:(2):2000;85-93.
97. Lankas G.R., Cartwright M.E., Umbenhaurer D. P-glycoprotein deficiency in a subpopulation of CF-1 mice enhances avermectin-induced neurotoxicity. Toxicol. Appl. Pharmacol. 143:(2):1997;357-365.
98. Umbenhaurer D., Lankas G.R., Pippert T.R., Wise L.D., Cartwright M.E., Hall S.J., Beare C.M. Identification of a P-glycoprotein-deficient subpopulation in the CF-1 mouse strain using a restriction fragment length polymorphism. Toxicol. Appl. Pharmacol. 146:(1):1997;88-94.
99. Kwei G.Y., Alvaro R.F., Chen Q., Jenkins H.J., Hop C.E., Keohane C.A., Ly V.T., Strauss J.R., Wang R.W., Wang Z., Pippert T.R., Umbenhauer D.R. Disposition of ivermectin and cyclosporin A in CF-1 mice deficient in mdr1a P-glycoprotein. Drug Metab. Dispos. 27:(5):1999;581-587.
100. Dagenais C., Rousselle C., Pollack G.M., Scherrmann J.M. Development of an in situ mouse brain perfusion model and its application to mdr1a P-glycoprotein-deficient mice. J. Cereb. Blood Flow Metab. 20:(2):2000;381-386.
101. Liu J., Liu Y., Powell D.A., Waalkes M.P., Klaassen C.D. Multidrug-resistance mdr1a/1b double knockout mice are more sensitive than wild type mice to acute arsenic toxicity, with higher arsenic accumulation in tissues. Toxicology. 170:(1-2):2002;55-62.
102. Yamazaki M., Neway W.E., Ohe T., Chen I., Rowe J.F., Hochman J.H., Chiba M., Lin J.H. In vitro substrate identification studies for P-glycoprotein-mediated transport: Species difference and predicatability of in vivo results. J. Pharmacol. Exp. Ther. 296:(3):2001;723-735.
103. Adachi Y., Suzuki H., Sugiyama Y. Comparative studies on in vitro methods for evaluating in vivo function of MDR1 P-glycoprotein. Pharm. Res. 18:(12):2001;1660-1668.
104. Smith B.J., Doran A.C., McLean S., Tingley F.D. 3rd, O'Neill B.T., Kajiji S.M. P-glycoprotein efflux at the blood-brain barrier mediates differences in brain disposition and pharmacodynamics between two structurally related beurokinin-1 receptor antagonists. J. Pharmacol. Exp. Ther. 298:(3):2001;1252-1259.
105. Sawchuk R.J., Elmquist W.F. Microdialysis in the study of drug transporters in the CNS. Adv. Drug Deliv. Rev. 45:(2-3):2000;295-307.
106. Wang Q., Yang H., Miller D.W., Elmquist W.F. Effect of the p-glycoprotein inhibitor, cyclosporin A, on the distribution of rhodamine-123 to the brain: An in vivo microdialysis study in freely moving rats. Biochem. Biophys. Res. Commun. 211:(3):1995;719-726.
107. de Lange E.C., de Bock G., Schinkel A.H., de Boer A.G., Breimer D.D. BBB transport and P-glycoprotein functionality using MDR1A (-/-) and wild-type mice. Total brain versus microdialysis concentration profiles of rhodamine-123. Pharm. Res. 15:(11):1998;1657-1665.
108. Tsai T.H. Pharmacokinetics of pefloxacin and its interaction with cyclosporin A, a P-glycoprotein modulator, in rat blood, brain and bile, using simultaneous microdialysis. Br. J. Pharmacol. 132:(6):2001;1310-1316.
109. Chang Y.L., Chou M.H., Lin M.F., Chen C.F., Tsai T.H. Effect of cyclosporin, a P-glycoprotein inhibitor, on the pharmacokinetics of cefepime in rat blood and brain: A microdialysis study. Life. Sci. 69:(2):2001;191-199.
110. Tsai T.H., Lee C.H., Yeh P.H. Effect of P-glycoprotein modulators on the pharmacokinetics of camptothecin using microdialysis. Br. J. Pharmacol. 134:(6):2001;1245-1252.
111. Dan Y., Murakami H., Koyabu N., Ohtani H., Sawada Y. Distribution of domperidone into the rat brain is increased by brain ischaemia or treatment with the P-glycoprotein inhibitor verapamil. J. Pharm. Pharmacol. 54:(5):2002;729-733.
112. Potschka H., Fedrowitz M., Loscher W. P-glycoprotein and multidrug resistance-associated protein are involved in the regulation of extracellular levels of the major antiepileptic drug carbamazepine in the brain. Neuroreport. 12:(16):2001;3557-3560.
113. Potschka H., Loscher W. In vivo evidence for P-glycoprotein-mediated transport of phenytoin at the blood-brain barrier of rats. Epilepsia. 42:(10):2001;1231-1240.
114. N.H. Handrikse, W. Vaalburg, Imaging of P-glycoprotein function in vivo with PET, Novartis Found. Symp., 243(2002) 137-45, 145-8, 180-5.
115. N.H. Handrikse, J. Bart, E.G. de Vries, H.J. Groen, W.T. van der Graaf, W. Vaalburg, P-glycoprotein at the blood-brain barrier and analysis of drug transport with positron-emission tomography, J. Clin. Pharmacol., Suppl. (2001) 48S-54S.
116. Doze P., Van Waarde A., Elsinga P.H., Hendrikse N.H., Vaalburg W. Enhanced cerebral uptake of receptor ligands by modulation of P-glycoprotein function in the blood-brain barrier. Synapse. 36:(1):2000;66-74.
117. Handrikse N.H., de Vries E.G., Eriks-Fluks L., van der Graaf W.T., Hospers G.A., Willemsen A.T., Vaalburg W., Franssen E.J. A new in vivo method to study P-glycoprotein transport in tumors and the blood-brain barrier. Cancer Resm. 59:(10):1999;2411-2416.
118. Handrikse N.H., Schinkel A.H., de Vries E.G., Fluks E., van der Graaf W.T., Willemsen A.T., Vaalburg W., Franssen E.J. Complete in vivo reversal of P-glycoprotein pump function in the blood-brain barrier visualized with positron emission tomography. Br. J. Pharmacol. 124:(7):1998;1413-1418.
119. 18F]MPPF in rats. Eur. J. Pharmacol. 407:(3):2000;273-280.
120. Luker G.D., Rao V.V., Crankshaw C.L., Dahlheimer J., Piwnica-Worms D. Characterization of phosphine complexes of technetium(III) as transport substrates of the multidrug resistance P-glycoprotein and functional markers of P-glycoprotein at the blood-brain barrier. Biochemistry. 36:(46):1997;14218-14227.
121. Chen W.S., Luker K.E., L Dahlheimer J., Pica C.M., Luker G.D., Piwnica-Worms D. Effects of MDR1 and MDR3 P-glycoprotein, MRP1, and BCRP/MXR/ABCP on the transport of (99m) Tc-tetrofosmin. Biochem. Pharmacol. 60:(30):2000;413-426.
122. Cole S.P.C., Bhardwaj G., Gerlach J.H., Mackie J.E., Grant C.E., Almquist K.C., Stewart A.J., Kurz E.U., Duncan A.M.V., Deeley G.R. Overexpression of a transporter gene in a multidrug-resistant human lung cancer cell line. Science. 258:1992;1650-1654.
123. Flens M.J., Zaman G.J.R., Van der Valk P., Izquierdo M.A., Schroeijers A.B., Scheffer G.L., De Hass M., Meijer C.J.L.M., Scheper R.J. Am. J. Pathol. 148:1996;1237-1247.
124. Buchler M., Konig J., Brom M., Kartenbeck J., Spring H., Horie T., Keppler D. cDNA cloning of the hepatocyte canalicular isoform of the multidrug resistance protein, cMrp, reveals a novel conjugate export pump deficient in hyperbilirubinemic mutant rats. J. Biol. Chem. 271:1996;15091-15098.
125. Taniguchi K., Wada M., Kohno K., Nakamura T., Kawabe T., Kawakami M., Kagotani K., Okumura K., Akiyama S., Kuwano M. A human canalicular multispecific organic anion transporter (cMOAT) gene is overexpressed in cisplatin-resistant human cancer cell lines with decreased drug accumulation. Cancer Res. 56:1996;4124-4129.
126. Kool M., de Haas M., Scheffer G.L., Scheper R.J., van Eijk M.J.K., Juijn J.A., Baas F., Borst P. Analysis of expression of cMOAT (MRP2), MRP2, MRP4, and MRP5, Homologues of the multidrug resistance-associated protein gene (MRP1), in human cancer cell lines. Cancer Res. 57:1997;3537-3547.
127. Kool M., van der Linden M., De Haas M., Baas F., Borst P. Expression of MRP6, a homologue of the multidrug resistance protein gene MRP1, in tissues and cancer cells. Cancer Res. 59:(1):1999;175-182.
128. Hopper E., Belinsky M.G., Zeng H., Tosolini A., Testa J.R., Kruh G.D. Analysis of the structure and expression pattern of MRP7 (ABCC10), a new member of the MRP subfamily. Cancer Lett. 162:(2):2001;181-191.
129. Kao H.H., Huang J.D., Chang M.S. cDNA cloning and genomic organization of the murine MRP7, a new ATP-binding cassette transporter. Gene. 286:(2):2002;299-306.
130. Bera T.K., Lee S., Salvatore G., Lee B., Pastan I. MRP8, a new member of the ABC transporter superfamily, identified by EST database mining and gene prediction program, is highly expressed in breast cancer. Mol. Med. 7:(8):2001;509-516.
131. Bera T.K., Iavarone C., Kumar V., Lee S., Lee B., Pastan I. MRP9, an unusual truncated member of the ABC transporter superfamily, is highly expressed in breast cancer. Proc. Natl. Acad. Sci. 99:(10):2002;6997-7002.
132. Kusuhara H., Suzuki H., Naito M., Tsuruo T., Sugiyama Y. Characterization of efflux transport of organic anions in a mouse brain capillary endothelial cell line. J. Pharmacol. Exp. Ther. 285:1998;1260-1265.
133. Homma M., Suzuki H., Kusuhara H., Naito M., Tsuruo T., Sugiyama Y. High-affinity efflux transport system for glutathione conjugate on the luminal membrane of a mouse brain capillary endothelial cell line (MBEC4). J. Pharmacol. Exp. Ther. 288:1999;198-203.
134. Ghersi-Egea J.F., Leininger B., Suleman G., Minn A. Localization of drug-metabolizing enzyme activities to blood-brain interfaces and circumventricular organs. J. Neurochem. 62:1994;1089-1096.
135. Huai-Yun H., Secrest D.T., Mark K.S., Carney D., Brandquist C., Elmquist W.F., Miller D.W. Expression of multidrug resistance protein (MRP) in brain microvessel endothelial cells. Biochem. Biophys. Res. Commun. 243:(3):1998;816-820.
136. Zhang Y., Han H., Elmquist W.F., Miller D.W. Expression of multidrug resistance-associated protein (MRP) homologues in brain microvessel endothelial cells. Brain. Res. 876:2000;148-153.
137. Sun H., Johnson D.R., Finch R.A., Sartorelli A.C., Miller D.W., Elmquist W.F. Transport of fluorescein in MDCKII-MRP1 transfected cells and mrp1-knockout mice. Biochem. Biophys. Res. Commun. 284:2001;863-869.
138. Sun H., Miller D.W., Elmquist W.F. Effect of probenecid on fluorescein transport in the central nervous system using in vitro and in vivo models. Pharm. Res. 18:(11):2001;1542-1549.
139. Seetharaman S., Barrand M.A., Maskell L., Sheper R.J. Multidrug resistance-related transport proteins in isolated human brain microvessels and in cells cultured from these isolates. J. Neurochem. 70:1998;1151-1159.
140. Gutmann H., Torok M., Fricker G., Huwyler J., Beglinger C., Drewe J. Modulation of multidrug resistance protein expression in porcine brain capillary endothelial cells in vitro. Drug. Metab. Dispos. 27:1999;937-941.
141. Regina A., Koman A., Piciotti M., Hafny B.E., Center M.S., Bergmann R., Couraud P.O., Roux F. Mrp1 Multidrug resistance-associated protein and P-glycoprotein expression in rat brain microvessel endothelial cells. J. Neurochem. 71:1998;705-715.
142. Wijnholds J., de Lange E.C.M., Scheffer G.L., van den Berg D.J., Mol C.A.A.M., van der Valk M., Schinkel A.H., Scheper R.J., Breimer D.D., Borst P. Multidrug resistance protein 1 protects the choroid plexus epithelium and contributes to the blood-cerebrospinal fluid barrier. J. Clin. Invest. 105:2000;279-285.
143. Seetharaman S., Maskell L., Scheper R.J., Barrand M.A. Changes in multidrug transporter protein expression in endothelial cells cultured from isolated human brain microvessels. Int. J. Clin. Pharmacol. Ther. 36:(2):1998;81-83.
144. McAleer M.A., Breen M.A., White N.L., Mattews N. pABC11 (Also known as MOAT-C and MRP5). A member of the ABC family of proteins, has anion transporter activity but dose not confer multidrug resistance when overexpressed in human embryonic kidney 293 cells. J. Biol. Chem. 274:1999;23541-23548.
145. Wijnholds J., Mol C.A.A.M., van Deemter L., de Haas M., Scheffer G.L., Baas F., Beijnen J.H., Scheper R.J., Hatse S., Clercq E.D., Balzarini J., Borst P. Multidrug-resistance protein 5 is a multispecific organic anion transporter able to transport nucleotide analogs. Proc. Natl. Acad. Sci. USA. 97:2000;7476-7481.
146. Jedlitschky G., Burchell B., Keppler D. The multidrug resistance protein 5(MRP5) functions as an ATP-dependent export pump for cyclic
147. Sweet D.H., Miller D.S., Pritchard J.B., Fujiwara Y., Beier D.R., Nigam S.K. Impaired organic anion transport in kidney and choroids plexus of organic anion transporter 3 (Oat3(Slc22a8)) knockout mice. J. Biol. Chem. 277:(30):2002;26934-36943.
148. Takasawa K., Suzuki H., Sugiyama Y. In vivo evidence for carrier-mediated efflux of 3′-azido-3′-deoxythymidine and 2′, 3′-dideoxyinosine across the blood-brain barrier via a probenecid-sensitive transport system. J. Pharmacol. Exp. Ther. 281:1997;369-375.
149. Kitazawa T., Terasaki T., Suzuki H., Kakee A., Sugiyama Y. Efflux of taurocholic acid across the blood-brain barrier: Interaction with cyclic peptides. J. Pharmacol. Exp. Ther. 286:1998;890-895.
150. Wada S., Tsuda M., Sekine T., Cha S.H., Kimura M., Kanai Y., Endou H. Rat multispecific organic anion transporter 1 (rOAT1) transports zidovudine, acyclovir, and other antiviral nucleoside analogs. J. Pharmacol. Exp. Ther. 294:2000;844-849.
151. Kusuhara H., Sekine T., Utsunomiya-Tate N., Tsuda M., Kojima R., Cha S.H., Sugiyama Y., Kanai Y., Endou H. Molecular cloning and characterization of a new multispecific organic anion transporter from rat brain. J. Biol. Chem. 274:1999;13675-13680.
152. Sekine T., Cha S.H., Endou H. The multispecific organic anion transporter (OAT) family. Pflugers. Arch - Eur. J. Physiol. 440:2000;337-350.
153. Sekine T., Watanabe N., Hosoyamada M., Kanai Y., Endou H. Expression cloning and characterization of a novel multispecific organic anion transporter. J. Biol. Chem. 272:1997;18526-18529.
154. Asaba H., Hosoya K., Takanaga H., Ohtsuki S., Tamura E., Takizawa T., Terasaki T. Blood-brain barrier is involved in the efflux transport of a neuroactive steroid, dehydroepiandrosterone sulfate, via organic anion transporting polypeptide 2. J. Neurochem. 75:2000;1907-1916.
155. Gerhart D.Z., Enerson B.E., Zhdankina O.Y., Leino R.L., Drewes L.R. Expression of monocarboxylate transporter MCT1 by brain endothelium and glia in adult and suckling rats. Am. J. Physiol. 273:1997;E207-213.
156. Kido Y., Tamai I., Okamoto M., Suzuki F., Tsuji A. Functional clarification of MCT1-mediated transport of monocarboxylic acids at the blood-brain barrier using in vitro cultured cells and in vivo BUI studies. Pharm. Res. 17:2000;55-62.
157. Leier I., Jedlitschky G., Buchholz U., Cole S.P., Deeley R.G., Keppler D. The MRP gene encodes an ATP-dependent export pump for leukotriene C4 and structurally related conjugates. J. Biol. Chem. 269:(45):1994;27807-27810.
158. Evers R., Kool M., van Deemter L., Janssen H., Calafat J., Oomen L.C., Paulusma C.C., P Oude Elferink R., Baas F., Schinkel A.H., Borst P. Drug export activity of the human canalicular multispecific organic anion transporter in polarized kidney MDCK cells expressing cMOAT (MRP2) cDNA. J. Clin. Invest. 101:1998;1310-1319.
159. Jedlitschky G., Leier I., Buchholz U., Barnouin K., Kurz G., Keppler D. Transport of glutathione, glucuronate, and sulfate conjugates by the MRP gene-encoded conjugate export pump. Cancer Res. 56:1996;988-994.
160. Loe D.W., Almquist K.C., Deeley R.G., Cole S.P. Multidrug resistance protein (MRP)-mediated transport of leukotriene C4 and chemotherapeutic agents in membrane vesicles. Demonstration of glutathione-dependent vincristine transport. J. Biol. Chem. 271:1996;9675-9682.
161. Leier I., Jedlitschky G., Buchholz U., Center M., Cole S.P., Deeley R.G., Keppler D. ATP-dependent glutathione disulphide transport mediated by the MRP gene-encoded conjugate export pump. Biochem. J. 314:1996;433-437.
162. Loe D.W., Stewart R.K., Massey T.E., Deeley R.G., Cole S.P. ATP-dependent transport of aflatoxin B1 and its glutathione conjugates by the product of the multidrug resistance protein (MRP) gene. Mol. Pharmacol. 51:1997;1034-1041.
163. Zaman G.J., Cnubben N.H., van Bladereb P.J., Evers R., Borst P. Transport of the glutathione conjugate of ethacrynic acid by the human multidrug resistance protein MRP. FEBS Lett. 391:1996;126-130.
164. Evers R., Cnubben N.H., Wijnholds J., van Deemter L., van Bladeren P.J., Borst P. Transport of glutathione prostaglandin A conjugates by the multidrug resistance protein 1. FEBS Lett. 419:1997;112-116.
165. r 190 000 multidrug resistance protein (MRP): Evidence for cotransport with reduced glutathione. Cancer Res. 58:1998;5130-5136.
166. Renes J., de Vries E.G., Nienhuis E.F., Jansen P.L., Muller M. ATP- and glutathione-dependent transport of chemotherapeutic drugs by the multidrug resistance protein MRP1. Br. J. Pharmacol. 126:1999;681-688.
167. Keppler D., Cui Y., Konig J., Leier I., Nies A. Export pumps for anionic conjugates encoded by MRP genes. Adv. Enz. Regul. 39:1999;237-246.
168. Hooijberg J.H., Broxterman H.J., Kool M., Assaraf Y.G., Peters G.J., Noordhuis P., Scheper R.J., Borst P., Pinedo H.M., Jansen G. Antifolate resistance mediated by the multidrug resistance proteins MRP1 and MRP2. Cancer Res. 59:1999;2532-2535.
169. Schuetz J.D., Connelly M.C., Sun D., Paibir S.G., Flynn P.M., Srinivas R.V., Kumar A., Fridland A. MRP4: A previously unidentified factor in resistance to nucleoside-based antiviral drugs. Nature Med. 5:1999;1048-1051.
170. Madon J., Hagenbuch B., Landmann L., Meier P.J., Stieger B. Transport function and hepatocellular localization of mrp6 in rat liver. Mol. Pharmacol. 57:2000;634-641.
171. +-independent organic anion transporter. Proc. Natl. Acad. Sci. USA. 91:1994;133-137.
172. Li L.Q., Lee T.K., Meier P.J., Ballatori N. Identification of glutathione as a driving force and leukotriene C-4 as a substrate for Oatp1, the hepatic sinusoidal organic solute transporter. J Biol. Chem. 273:1998;16184-16191.
173. Eckhardt U., Schroeder A., Stieger B., Hochli M., Landmann L., Tynes R., Meier P.J., Hagenbuch B. Polyspecific substrate uptake by the hepatic organic anion transporter Oatp1 in stably transfected CHO cells. Am. J. Physiol. 276:1999;G1037-G1042.
174. Bossuyt X., Muller M., Hagenbuch B., Meier P.J. Polyspecific drug and steroid clearance by an organic anion transporter of mammalian liver. J. Pharmacol. Exp. Ther. 276:1996;891-896.
175. van Aubel R.A.M.H., Masereeuw R., Russel F.G.M. Molecular pharmacology of renal organic anion transporters. Am. J. Physiol. Renal Physiol. 279:2000;F216-F232.
176. van Montfoort J.E., Hagenbuch B., Fattinger K.E., Muller M., Groothuis G.M.M., Meijer D.K.F., Meier P.J. Polyspecific organic anion transporting polypeptides mediate hepatic uptake of amphipathic type II organic cations. J. Pharmacol. Exp. Ther. 291:1999;147-152.
177. Eckhardt U., Horz J.A., Petzinger E., Stuber W., Reers M., Dickneite G., Daniel H., Wagener M., Hagenbuch B., Stieger B., Meier P.J. The peptide-based thrombin inhibitor CRC 220 is a new substrate of the basolateral rat liver organic anion-transporting polypeptide. Hepatology. 24:1996;380-384.
178. Pang K.S., Wang P.J., Chung A., Wolkoff A.W. The modified dipeptide, enalapril, an angiotensin-converting enzyme inhibitor, is transported by the rat liver organic anion transport protein. Hepatology. 28:1998;1341-1346.
179. Ishizuka H.K., Konno H., Naganuma K., Nishimura H., Kouzuki H., Suzuki H., Stieger B., Meier P.J., Sugiyama Y. Transport of temocaprilat into rat hepatocytes: Role of organic anion transporting polypeptide. J. Pharmacol. Exp. Ther. 287:1998;37-42.
180. Gao B., Hagenbuch B., Kullak-Ublick G.A., Benke D., Aguzzi A., Meier P.J. Organic anion-transporting polypeptides mediate transport of opioid peptides across blood-brain barrier. J. Pharmacol. Exp. Ther. 294:2000;73-79.
181. Kontaxi M., Eckhardt U., Hagenbuch B., Stieger B., Meier P.J., Petzinger E. Uptake of the mycotoxin ochratoxin A in liver cells occurs via the cloned organic anion transporting polypeptide. J. Pharmacol. Exp. Ther. 279:1996;1507-1513.
182. Reichel C., Gao B., van Montfoort J., Cattori V., Rahner C., Hagenbuch B., Stieger B., Kamisako T., Meier M.J. Localization and function of the organic anion-transporting polypeptide Oatp2 in rat liver. Gastroenterology. 117:1999;688-695.
183. Friesema E.C., Docter R., Moerings E.P., Stieger B., Hagenbuch B., Meier P.J., Krenning E.P., Hennemann G., Visser T.J. Identification of thyroid hormone transporters. Biochem. Biophys. Res. Commun. 254:1999;497-501.
184. Noe B., Hagenbuch B., Stieger B., Meirer P.J. Isolation of a multispecific organic anion and cardiac glycoside transporter from rat brain. Proc. Natl. Acad. Sci. USA. 94:1997;10346-10350.
185. Abe T., Kakyo M., Sakagami H., Tokui T., Nishio T., Tanemoto M., Nomura H., Hebert S.C., Matsuno S., Kondo H., Yawo H. Molecular characterization and tissue distribution of a new organic transporter subtype (oatp3) that transports thyroid hormones and taurocholate and comparison with oatp2. J. Biol. Chem. 273:1998;22395-22401.
186. Kullak-Ublick G.A., Hagenbuch B., Stieger B., Schteingart C.D., Hofmann A.F., Wolkoff A.W., Meier P.J. Molecular and functional characterization of an organic anion transporting polypeptide cloned from human liver. Gastroenterology. 109:1995;1274-1282.
187. Bossuyt X., Muller M., Meier P.J. Multispecific amphipathic substrate transport by an organic anion transporter of human liver. J. Hepatol. 25:1996;733-738.
188. Kullak-Ublick G.A. Regulation of organic anion and drug transporters of the sinusoidal membrane. J. Hepatol. 31:1999;563-573.
189. Uwai Y., Okuda M., Takami K., Hashimoto Y., Inui K. Functional characterization of the rat multispecific organic anion transporter OAT1 mediating basolateral uptake of anionic drugs in the kidney. FEBS. Lett. 438:(3):1998;321-324.
190. Apiwattanakul N., Sekine T., Chairoungdua A., Kanai Y., Nakajima N., Sophasan S., Endou H. Transport properties of nonsteroidal anti-inflammatory drugs by organic anion transporter 1 expressed in Xenopus laevis oocytes. Mol. Pharmacol. 55:(5):1999;847-854.
191. Tsuda M., Sekine T., Takeda M., Cha S.H., Kanai Y., Kimura M., Endou H. Transport of ochratoxin A by renal multispecific organic anion transporter 1. J. Pharmacol. Exp. Ther. 289:1999;1301-1305.
192. Jariyawat S., Sekine T., Takeda M., Apiwattanakul N., Kanai Y., Sophasan S., Endou H. The interaction and transport of β-lactam antibiotics with the cloned rat renal organic an transporter 1. J. Pharmacol. Exp. Ther. 290:1999;672-677.
193. Kakee A., Terasaki T., Sugiyama Y. Selective brain to blood efflux transport of p-aminohippuric acid across the blood-brain barrier: In vivo evidence by use of the brain efflux index method. J. Pharmacol. Exp. Ther. 283:1997;1018-1025.
194. Banks W.A., Schally A.V., Barrera C.M., Fasold M.B., Durham D.A., Csernus V.J., Groot K., Kastin A.J. Permeability of the murine blood-brain barrier to some octapeptide analogs of somatostatin. Proc. Natl. Acad. Sci. USA. 87:1990;6762-6766.
195. Banks W.A., Kastin A.J., Sam H.M., Cao V.T., King B., Maness L.M., Schally A.V. Saturable efflux of the peptides RC-160 and Tyr-MIF-1 by different parts of the blood-brain barrier. Brain Res. Bull. 35:1994;179-182.
196. Leininger B., Ghersi-Egea J.F., Siest G., Minn A. In vivo study of the elimination from rat brain of an intracerebrally formed xenobiotic metabolite, 1-naphthyl-β-D-glucuronide. J. Neurochem. 56:1991;1163-1168.
197. Cornford E.M., Diep C.P., Pardridge W.M. Blood-brain barrier transport of valproic acid. J. Neurochem. 44:1985;1541-1550.
198. Adkison K.D., Artru A.A., Powers K.M., Shen D.D. Contribution of probenecid-sensitive anion transport processes at the brain capillary endothelium and choroid plexus to the efficient efflux of valproic acid from the central nervous system. J. Pharmacol. Exp. Ther. 268:1994;797-805.
199. Adkison K.D., Artru A.A., Powers K.M., Shen D.D. Effect of p-aminohippurate on the efflux of valproic acid from the central nervous system of the rabbit. Epilepsy Res. 23:1996;95-104.
200. Scism J.L., Powrs K.M., Artru A.A., Chambers A.C., Lewis L., Adkison K.K., Kalhorn T.F., Shen D.D. Effects of probenecid on brain-cerebrospinal fluid-blood distribution kinetics of E-Delta 2-valproic acid in rabbits. Drug Metab. Dispos. 25:1997;1337-1346.
201. Emanuelsson B.M., Paalzow L., Sunzel M. Probenecid-induced accumulation of 5-hydroxyindoleacetic acid and homovanillic acid in rat brain. J. Pharm. Pharmacol. 39:1987;705-710.
202. Morrison P.F., Morishige G.M., Beagles K.E., Heyes M.P. Quinolinic acid is extruded from the brain by a probenecid-sensitive carrier system: A quantitative analysis. J. Neurochem. 72:1999;2135-2144.
203. Deguchi Y., Yokoyama Y., Sakamoto T., Hayashi H., Naito T., Yamada S., Kimura R. Brain distribution of 6-mercaptopurine is regulated by the efflux transport system in the blood-brain barrier. Life. Sci. 66:2000;649-662.
204. Deguchi Y., Inabe K., Tomiyasu K., Nozawa K., Yamada S., Kimura R. Study on brain interstitial fluid distribution and blood-brain barrier transport of baclofen in rats by microdialysis. Pharm. Res. 12:1995;1838-1844.
205. Bergeron M., Swain M.S., Molina-Holgado E., Reader T.A., Butterworth R.F. Effect of probenecid on 5-hydroxyindoleacetic acid in cisternal cerebrospinal fluid of rats with portacaval anastomosis. Neurochem. Res. 20:1995;963-967.
206. Kim C.S., Keizer R.F., Ambrose W.W., Breese G.R. Effect of 2, 4, 5-trichlorophenoxyacetic acid and quinolinic acid on 5-hydroxy-3-indoleacetic acid transport by the rabbit choroid plexus: Pharmacology and electron microscopic cytochemistry. Toxicol. Appl. Pharmacol. 90:1987;436-444.
207. Kim C.S., Roe C.R., Mann J.D., Breese G.R. Octanoic acid produces accumulation of monoamine acidic metabolites in the brain: Interaction with organic anion transport at the choroid plexus. J. Neurochem. 58:1992;1499-1503.
208. Spector R. Inhibition of methotrexate transport from cerebrospinal fluid by probenecid. Cancer Treat Rep. 60:1976;913-916.
209. 14C-penicillin from cerebrospinal fluid to blood. J. Pharm. Sci. 58:1969;1106-1109.
210. Ogawa M., Suzuki H., Sawada Y., Hanano M., Sugiyama Y. Kinetics of active efflux via choroid plexus of β-lactam antibiotics from the CSF into the circulation. Am. J. Physiol. 266:1994;R392-399.
211. Ooie T., Suzuki H., Terasaki T., Sugiyama Y. Characterization of the transport properties of quinolone antibiotic, fleroxacin, in rat choroid plexus. Pharm. Res. 13:1996;523-527.
212. Nohjoh T., Suzuki H., Sawada Y., Sugiyama Y., Iga T., Hanano M. Transport of cefodizime, a novel third generation cephalosporin antibiotic, in isolated rat choroid plexus. J. Pharmacol. Exp. Ther. 250:1989;324-328.
213. Kim C.S., Pritchard J.B. Transport of 2, 4, 5-trichlorophenoxyacetic acid across the blood-cerebrospinal fluid barrier of the rabbit. J. Pharmacol. Exp. Ther. 267:1993;751-757.
214. Pritchard J.B. Accumulation of anionic pesticides by rabbit choroid plexus in vitro. J. Pharmacol. Exp. Ther. 212:1980;54-59.
215. Nishino J., Suzuki H., Sugiyama D., Kitazawa T., Ito K., Hanano M., Sugiyama Y. Transepithelial transport of organic anions across the choroid plexus: Possible involvement of organic anion transporter and multidrug resistance-associated protein. J. Pharmacol. Exp. Ther. 290:1999;289-294.
216. Takasawa K., Suzuki H., Sugiyama Y. Transport properties of 3′-azido-3′-deoxythymidine and 2′, 3′-dideoxyinosine in the rat choroid plexus. Biopharm. Drug Disposition. 18:1997;611-622.
217. Masereeuw R., Jaehde U., Langemeijer M.W., de Boer A.G., Breimer D.D. In vitro and in vivo transport of zidovudine (AZT) across the blood-brain barrier and the effect of transport inhibitors. Pharm. Res. 11:1994;324-330.
218. Wang Y., Wei Y., Sawchuk R.J. Zidovudine transport within the rabbit brain during intracerebroventricular administration and the effect of probenecid. J. Pharm. Sci. 86:1997;1484-1490.
219. Kitazawa T., Hosoya K., Takahashi T., Sugiyama Y., Terasaki T. In vivo and in vitro evidence of a carrier-mediated efflux transport system for oestrone-3-sulphate across the blood-cerebrospinal fluid barrier. J. Pharm. Pharmacol. 52:2000;281-288.
220. 4 transport by the choroid plexus in vitro. Science. 228:(4697):1985;325-327.
221. Spector R. Pantothenic acid transport and metabolism in the central nervous system. Am. J. Physiol. 250:1986;R292-297.
222. Suzuki H., Sawada Y., Sugiyama Y., Iga T., Hanano M. Transport of cimetidine by the rat choroid plexus in vitro. J. Pharmacol. Exp. Ther. 239:1986;927-935.
223. Naora K., Ichikawa N., Nishimura N., Hirano H., Shen D.D., Iwamoto K. Saturable transport of valproic acid in rat choroid plexus in vitro. J. Pharm. Sci. 85:1996;423-426.
224. Kanai N., Lu R., Bao Y., Wolkoff A.W., Vore M., Schuster V.L. Estrdiol 17β-D-glucuronide is a high-affinity substrate for oatp organic anion transporter. Am. J. Physiol. 270:1996;F326-F331.
225. Kanai N., Lu R., Satriano J.A., Bao Y., Wolkoff A.W., Schuster V.L. Identification and characterization of a prostaglandin transporter. Science (Wash. DC). 268:1995;866-869.
226. Gao B., Stieger B., Noe B., Fritschy J.M., Meier P.J. Localization of the organic anion transporting polypeptide 2 (Oatp2) in capillary endothelium and choroid plexus epithelium of rat brain. J. Histochem. Cytochem. 47:1999;1255-1264.
227. Walters H.C., Craddock A.L., Fusegawa H., Willingham M.C., Dawson P.A. Expression, transport properties, and chromosomal location of organic anion transporter subtype 3. Am. J. Physiol. Gastroinest. Liver Physiol. 279:(6):2000;1188-1200.
228. Y. Zhang, J.D. Schuetz, W.F. Elmquist, D.W. Milller, Plasma membrane localization of multidrug resistance-associated protein (MRP) homologues in brain capillary endothelial cells, J. Neurochem., submitted for publication.
229. Sugiyama D., Kusuhara H., Shitara Y., Abe T., Meier P.J., Sekine T., Endou H., Suzuki H., Sugiyama Y. Characterization of efflux transport of 17 β-estradiol-D-glucuronide from the brain across the blood-brain barrier. J. Pharmacol. Exp. Ther. 298:(1):2001;316-322.
230. Gibbs J.E., Thomas S.A. The distribution of the anti-HIV drug, 2′3′-dideoxycytidine(ddC), across the blood-brain barrier and blood-cerebrospinal fluid barriers and the influence of organic anion transport inhibitors. J. Neurochem. 80:(3):2002;392-404.
231. Miller D.S., Nobmann S.N., Gutmann H., Toeroek M., Drewe J., Fricker G. Xenobiotic transport across isolated brain microvessels studied by confocal microscopy. Mol. Pharmacol. 58:(6):2000;1357-1367.
232. Pritchard J.B., Sweet D.H., Miller D.S., Walden R. Mechanism of organic anion transport across the apical membrane of choroid plexus. J. Biol. Chem. 274:(47):1999;33382-33387.
233. Angeletti R.H., Novikoff P.M., Juvvadi S.R., M Fritschy J., J Meier P., Wolkoff A.W. The choroid plexus epithelium is the site of the organic anion transport protein in the brain. Proc. Natl. Acad. Sci. USA. 94:1997;283-286.